UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Pediatric Solid Tumor

Interventions

DRUG

Irinotecan (CPT-11)

Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.

DRUG

Temozolomide (TMZ)

TMZ：100mg/m2/d，d1-5

DRUG

Vincristine

VCR: 1.5mg/m2/d(≯2mg), d1

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER